IPO Failures Can Set Up Biotech Successes
This article was originally published in Start Up
Executive Summary
Did the 31 biotechs who pulled IPOs since 2003 destroy value? By and large, no-thanks to a growing variety of financing and exit options, most thanks to Pharma's increasing appetite for high-value deals and deeper private equity pockets.